Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
Not Confirmed
Not Confirmed
07-10 June, 2026
Not Confirmed
Not Confirmed
09-11 June, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS





Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
Industry Trade Show
Not Confirmed
07-10 June, 2026
Industry Trade Show
Not Confirmed
09-11 June, 2026
Digital content

08 Jun 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/2026-ada--innovent-presents-multiple-clinical-and-preclinical-results-of-next-generation-obesity--metabolic-pipeline-302793636.html

04 Jun 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/worlds-first-cldn18-2-adc-for-regulatory-review-innovent-biologics-announces-ibi343-arcotatug-tavatecan-met-primary-endpoint-in-international-phase-3-study-in-advanced-refractory-gastric-cancer-and-nda-accepted-by-china-nmpa-302791220.html

01 Jun 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/2026-asco--innovent-presents-preliminary-poc-data-of-ibi363-tak-928-pd-1il-2-bias-bispecific-fusion-protein-in-first-line-advanced-nsclc-302786452.html

31 May 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/2026-asco--innovent-presents-long-term-follow-up-results-from-the-poc-study-of-ibi363-tak-928-pd-1il-2-bias-bispecific-fusion-protein-showing-robust-survival-benefits-in-advanced-immunotherapy-resistant-non-small-cell-lung-302786450.html

28 May 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/innovent-biologics-and-pfizer-enter-global-strategic-collaboration-to-accelerate-development-of-innovative-oncology-medicines-302785085.html

22 May 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/2026-asco-abstract-highlights--innovent-announces-preliminary-poc-data-of-ibi363-pd-1il-2-bias-bispecific-fusion-protein-in-combination-with-chemotherapy-as-first-line-treatment-for-advanced-nsclc-showing-encouraging-efficac-302779649.html
Inspections and registrations
Country : China
City/Region : Suzhou City, Jiangsu Province
Audit Date : 2026-04-24
Audit Type : On-Site
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE